A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University Hospital, Strasbourg, France
Sanford Health
Maastricht Radiation Oncology
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
University of Chicago
University of Chicago
University of Chicago
University of Chicago
University of Kentucky
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
H. Lee Moffitt Cancer Center and Research Institute
Arbeitsgemeinschaft medikamentoese Tumortherapie
National Institutes of Health Clinical Center (CC)
King Faisal Specialist Hospital & Research Center
University Hospital, Toulouse
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
Danish Head and Neck Cancer Group
Swedish Orphan Biovitrum
Virginia Commonwealth University
Medrobotics Corporation
University Hospital, Ghent
University of Minnesota
Memorial Sloan Kettering Cancer Center
University Hospital, Ghent
Eli Lilly and Company
SWOG Cancer Research Network
Icahn School of Medicine at Mount Sinai
Sanofi
Siemens Molecular Imaging
Vical